Skip to main content
. Author manuscript; available in PMC: 2017 Sep 6.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2009 May 8;75(4):1181–1186. doi: 10.1016/j.ijrobp.2008.12.026

Table 1.

Clinical profile

Group 1
(n=39)		 Group 2
(n=34)		 Total
(n=73)
Male:female 19:20 16:18 35:38
Age (yrs) at Dx: Median (range) 3.1 (0.9 – 10.1) 3.9 (1.5 – 20.5) 3.3 (0.9 –20.5)
Age (yrs) at RT: Median (range) 3.6 (1.4 – 10.7 4.6 (2.2 – 20.8) 4.2 (1.4 – 20.8)
Months from Dx to RT: Median (range) 7.5 (2.8 – 11.3) 8.2 (3.3 – 23.6) 7.8 (2.8 – 23.6)
MYCN amplification 17 (50%) of 34 6 (23%) of 26 23 (38%) of 60
Cranial sites*
  Calvarium, diffuse/localized 12/6 15/12 27/18
  Orbit, bilateral/unilateral 11/10 3/2 15/11
  Base of skull 6 4 10
  Mandible 6 3 9
Treatments
  Chemotherapy** induction alone 1 1 2
    + 3F8 7 16 23
    + SCT + 3F8 19 11 30
    + 131I-3F8 + 3F8 10 5 15
    + SCT 2 1 3

Dx, diagnosis; RT, radiotherapy; SCT, stem-cell transplantation.

*

Some patients had more than one site involved and irradiated.

**

N6/N7 chemotherapy regimen2 in 64 (88%) of the 73 patients.